Your browser does not support iframes.
Roth Capital lowered its price target on Dendreon Corp. (Nasdaq: DNDN) from $12 to $6.70 saying that the biotechnology firm's prostate cancer treatment Provenge may lose market share. The stock price fell 85 cents to $5.91.